Fig. 5: JNK1 enters the nucleus after treatment of sorafenib. | Cell Death & Disease

Fig. 5: JNK1 enters the nucleus after treatment of sorafenib.

From: Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma

Fig. 5

Flag-FOXQ1 or Flag-JNK1 was overexpressed in PLC/PRF/5, and the expression of Flag-FOXQ1 (A) or Flag-JNK1 (B) in the nucleus and cytoplasm was verified after DMSO or sorafenib (10 μM) treatment for 24 h. C, D After DMSO or sorafenib (10 μM) treatment for 24 h, the expression of FOXQ1 and JNK1 in the nucleus and cytoplasm was verified. E After PLC/PRF/5 and SK-Hep1 were treated with DMSO or sorafenib (10 μM) for 24 h, the changes in the binding amount of JNK1 and FOXQ1 were detected by immunoprecipitation.

Back to article page